Vikash Chandra

Honoured to receive support from #diabetestutkimus, #diabetefi for our ongoing #diabetesresearch @HelsinkiUniMed

Job alert...join us jobs.helsinki.fi/job-invite/385… #T1D #diabetesResearch #postdoc #postdocposition @HelsinkiUniMed

I am grateful to @novonordiskfond for funding a project grant to understand the mechanism for differential vulnerability of alpha and beta cells in #T1D through stem cells islets; looking for a motivated #postdoc ! @HelsinkiUniMed @helsinkiuni #Type1diabetes

🧬 Exciting new episode alert! 🧬 Join us as Vikash Chandra discusses potential candidate genes for drug targeting in #Type1Diabetes. Dive into groundbreaking insights and innovative research. Watch now: youtu.be/GGUGd3QFODs #DiabetesResearch #DrugDiscovery #TSS

Thursday! - 9 AM PT//12 PM ET 📢: tinyurl.com/3uhxm7mx @DiabetesnPOD @ULBCDiabRes @AMP_CMDKP @ufdiabete @IUSweetTweets @T1D_researchers @helmholtz_diabc @PennIDOM @DiabResearch @Diabetes_DRI @StanfordDRC @BCDiabResNet @JoslinDiabetes @Bruskolab @helsinkiuni @Dr_V_Chandra

Very happy to see our long-term project on the functional characterization of an RFX6 mutation enriched in Finns published in @DiabetologiaJnl. Superb work by @Hazemibrahimi. Read here: rdcu.be/dHX38

We're thrilled to announce that #EISG24_Helsinki 🇫🇮 is now SOLD OUT! 📷 Get ready for an exciting week of islet biology! We apologize to those who missed out, please register to the waiting list. We will consider the possibility of virtual attendance: elomake.helsinki.fi/lomakkeet/1289…

Register now to the European Islet Study Group meeting in Helsinki, Finland, 18-20 June 2024 🚨Early-bird registration and abstract deadline is approaching, do not miss your chance, limited seats availablea and they are quickly filling up! helsinki.fi/en/conferences……Please RT ;)

Thrilled to announce that registration and abstract submission for European Islet Study Group meeting in Helsinki, Finland, 18-20 June 2024 is NOW OPEN! helsinki.fi/en/conferences… 🚨Early-bird registration is March 15th, limited seats available🚨 Please RT ;)

LVM3 M4/Chandrayaan-3 Mission: LVM3 M4 vehicle🚀 successfully launched Chandrayaan-3🛰️ into orbit.

I love a muscle image, but this Drosophila one is top of the class! Beautiful Fly muscles m.cmpgn.page/xm2FMK?sre=RvJ… @andor

Great to present our latest research by Sophia at 19th Immunology of Diabetes Society #IDS #Paris 23 conference #T1d #Diabetes #Immunology @OtonkoskiL @Innodiagroup @HelsinkiUniMed @OtonkoskiT

Our research topic "Revisiting cellular metabolism and Type1 diabetes" is now online in @FrontEndocrinol frontiersin.org/research-topic… with @SwethaGopalakr2 and Latif Rachdi

According to a study @helsinkiuni, type 1 diabetes could be prevented by inhibiting a gene associated with the onset of the disease. @OtonkoskiL @OtonkoskiT @Dr_V_Chandra #WorldDiabetesDay helsinki.fi/en/news/public…

A promising drug candidate discovered for the prevention of type 1 #diabetes @helsinkiuni @NatureComms doi.org/gq5pxb medicalxpress.com/news/2022-11-d…

Our article is featured in the top 50 of the stem cells category @NatureComms nature.com/collections/pk…

Helsinkiläistutkijoilta hyviä uutisia tyypin 1 diabetesta sairastaville – lääke ehkä löydetty yle.fi/uutiset/74-200…

@johncallinan9 @OtonkoskiT @Hazemibrahimi @Innodiagroup BMS-986165

@OtonkoskiT @Dr_V_Chandra @Hazemibrahimi @Innodiagroup Was the drug they used Deucravacitinib which was recently approved by the FDA.

Great to see this out! @Dr_V_Chandra and @Hazemibrahimi were able to pinpoint a specific role for TYK2 in controlling the endocrine progenitor cell cycle. Collaborative effort within @Innodiagroup supports the use of TYK2 inhibitors for T1D prevention. rdcu.be/cYkB2

Kantasolututkimus paljastaa uuden palan diabeteksen mysteeripalapelistä! Voisiko TYK2 inhibiittori olla tyyppi 1 diabeteksen tulevaisuuden hoito?! Congrats Otonkoski-group! New avenues to treat type 1 diabetes! @HUS_fi @HelsinkiUniMed @Laakarilehti @DuodecimFi

Also on a brief note, feeling extremely honoured to be awarded docentship in experimental endocrinology from @HelsinkiUniMed Thanks to my mentor @OtonkoskiT and @OtonkoskiL for all the support 🙏

Glad to present our work TYK2 inhibition as a potential therapeutic target to halt #T1D progression. @OtonkoskiT @Hazemibrahimi @STEMMProgram @MetaStem_Center @helsinkiunimed @Innodiagroup @OtonkoskiL @NatureComms nature.com/articles/s4146…